VCP suppresses proteopathic seeding in neurons

Background: Neuronal uptake and subsequent spread of proteopathic seeds, such as αS (alpha-synuclein), Tau, and TDP-43, contribute to neurodegeneration. The cellular machinery participating in this process is poorly understood. One proteinopathy called multisystem proteinopathy (MSP) is associated w...

Full description

Bibliographic Details
Main Authors: Ayala, Y. (Author), Bieschke, J. (Author), Buscher, W.J (Author), Clemen, C.S (Author), Davis, A.A (Author), Dhavale, D. (Author), Diamond, M.I (Author), French, R. (Author), Kaleelurrrahuman, M.S (Author), Kotzbauer, P. (Author), Maggiore, G. (Author), Patterson, J.N (Author), Pittman, S. (Author), Sun, Y. (Author), Vaquer-Alicea, J. (Author), Weihl, C. (Author), Zhu, J. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Online Access:View Fulltext in Publisher
LEADER 04118nam a2200589Ia 4500
001 10.1186-s13024-022-00532-0
008 220511s2022 CNT 000 0 und d
020 |a 17501326 (ISSN) 
245 1 0 |a VCP suppresses proteopathic seeding in neurons 
260 0 |b BioMed Central Ltd  |c 2022 
856 |z View Fulltext in Publisher  |u https://doi.org/10.1186/s13024-022-00532-0 
520 3 |a Background: Neuronal uptake and subsequent spread of proteopathic seeds, such as αS (alpha-synuclein), Tau, and TDP-43, contribute to neurodegeneration. The cellular machinery participating in this process is poorly understood. One proteinopathy called multisystem proteinopathy (MSP) is associated with dominant mutations in Valosin Containing Protein (VCP). MSP patients have muscle and neuronal degeneration characterized by aggregate pathology that can include αS, Tau and TDP-43. Methods: We performed a fluorescent cell sorting based genome-wide CRISPR-Cas9 screen in αS biosensors. αS and TDP-43 seeding activity under varied conditions was assessed using FRET/Flow biosensor cells or immunofluorescence for phosphorylated αS or TDP-43 in primary cultured neurons. We analyzed in vivo seeding activity by immunostaining for phosphorylated αS following intrastriatal injection of αS seeds in control or VCP disease mutation carrying mice. Results: One hundred fifty-four genes were identified as suppressors of αS seeding. One suppressor, VCP when chemically or genetically inhibited increased αS seeding in cells and neurons. This was not due to an increase in αS uptake or αS protein levels. MSP-VCP mutation expression increased αS seeding in cells and neurons. Intrastriatal injection of αS preformed fibrils (PFF) into VCP-MSP mutation carrying mice increased phospho αS expression as compared to control mice. Cells stably expressing fluorescently tagged TDP-43 C-terminal fragment FRET pairs (TDP-43 biosensors) generate FRET when seeded with TDP-43 PFF but not monomeric TDP-43. VCP inhibition or MSP-VCP mutant expression increases TDP-43 seeding in TDP-43 biosensors. Similarly, treatment of neurons with TDP-43 PFFs generates high molecular weight insoluble phosphorylated TDP-43 after 5 days. This TDP-43 seed dependent increase in phosphorlyated TDP-43 is further augmented in MSP-VCP mutant expressing neurons. Conclusion: Using an unbiased screen, we identified the multifunctional AAA ATPase VCP as a suppressor of αS and TDP-43 aggregate seeding in cells and neurons. VCP facilitates the clearance of damaged lysosomes via lysophagy. We propose that VCP’s surveillance of permeabilized endosomes may protect against the proteopathic spread of pathogenic protein aggregates. The spread of distinct aggregate species may dictate the pleiotropic phenotypes and pathologies in VCP associated MSP. © 2022, The Author(s). 
650 0 4 |a Alpha-synuclein 
650 0 4 |a animal 
650 0 4 |a Animals 
650 0 4 |a CRISPR screen 
650 0 4 |a DNA binding protein 
650 0 4 |a DNA-Binding Proteins 
650 0 4 |a Frontotemporal dementia 
650 0 4 |a genetics 
650 0 4 |a human 
650 0 4 |a Humans 
650 0 4 |a metabolism 
650 0 4 |a Mice 
650 0 4 |a mouse 
650 0 4 |a mutation 
650 0 4 |a Mutation 
650 0 4 |a nerve cell 
650 0 4 |a Neurons 
650 0 4 |a Seeding 
650 0 4 |a TDP-43 
650 0 4 |a valosin containing protein 
650 0 4 |a Valosin Containing Protein 
650 0 4 |a VCP protein, human 
700 1 |a Ayala, Y.  |e author 
700 1 |a Bieschke, J.  |e author 
700 1 |a Buscher, W.J.  |e author 
700 1 |a Clemen, C.S.  |e author 
700 1 |a Davis, A.A.  |e author 
700 1 |a Dhavale, D.  |e author 
700 1 |a Diamond, M.I.  |e author 
700 1 |a French, R.  |e author 
700 1 |a Kaleelurrrahuman, M.S.  |e author 
700 1 |a Kotzbauer, P.  |e author 
700 1 |a Maggiore, G.  |e author 
700 1 |a Patterson, J.N.  |e author 
700 1 |a Pittman, S.  |e author 
700 1 |a Sun, Y.  |e author 
700 1 |a Vaquer-Alicea, J.  |e author 
700 1 |a Weihl, C.  |e author 
700 1 |a Zhu, J.  |e author 
773 |t Molecular Neurodegeneration